MAPT and tauopathy: Many therapies being developed for the treatment of tauopathies focus on managing tau pathology by i) targeting tau post-translational modifications, such as hyperphosphorylation; ii) preventing tau aggregation; iii) promoting clearance of existing aggregates by boosting cell’s protein degradation mechanisms or by directly targeting tau for degradation; and iv) reducing the pool of available tau.